Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction

Reduced Lpa with PCSK inhibitors in individuals with high Lpa at baseline contributes to CV risk reduction
3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc
  • Overview

    EAS 2019 Prof. Chapman lists the newest findings on the associations of Lp(a) levels, PCSK9 inhibitors and CV risk, based on new analyses of the FOURIER and ODYSSEY OUTCOMES trials.

  • Educational information

    This video was recorded at the EAS in Maastricht, the Netherlands, on May 29, 2019.

  • Faculty

    John Chapman is Research Professor at the Sorbonne University, is affiliated with the Endocrinology-Metabolism Division of the Pitié-Salpêtrière University Hospital, and is Director Emeritus of the National Institute for Health and Medical Research (INSERM) in Paris, France.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free